Study guide
2.1 PBS, Authority Prescriptions & Special Access Scheme
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
2.1 PBS, Authority Prescriptions & Special Access Scheme
Key Takeaways Explain This Topic AI
PBS supply requires a valid PBS prescription meeting eligibility, quantity, and authority rules; private (non-PBS) supply follows different pricing and still needs lawful schedule-based authority to supply
Authority Required scripts need prior approval (or a valid STREAMLINED authority code); pharmacists must verify authority particulars before claiming
Brand substitution is only appropriate when the brand is a-flagged as equivalent and the prescriber has not indicated 'brand substitution not permitted'
The Safety Net reduces further PBS patient contributions once a family's recorded PBS expenditure reaches the threshold in a calendar year
SAS Categories A, B, and C create pathways for unapproved medicines; supply must match the category pathway and documentation expected for that pathway
Last updated: August 2026
2.1 PBS, Authority Prescriptions & Special Access Scheme
Quick Answer: Under the Pharmaceutical Benefits Scheme (PBS), pharmacists supply subsidised medicines only when the prescription and patient meet PBS rules. Authority items need approval or a valid STREAMLINED code; brand substitution follows a-flagging and prescriber directions; Safety Net reduces contributions after a yearly threshold; and unapproved medicines may be supplied only through lawful pathways such as the Special Access Scheme (SAS).
Standard 1.3 of the National Competency Standards expects interns to practise within Australia's legal framework. PBS and SAS decisions are high-yield because small paperwork or eligibility errors change whether supply is lawful, claimable, or clinically appropriate.
PBS Versus Private (Non-PBS) Supply
The PBS is the Australian Government scheme that subsidises many listed medicines for eligible people (for example Medicare-eligible patients holding a valid Medicare card or equivalent eligibility arrangements). A PBS prescription must meet the scheme's legal and administrative requirements for the claim to be valid. A private prescription is not claimed as a PBS benefit: the patient pays the full private price (or uses other funding), but the medicine's schedule still governs whether supply is lawful.
- Feature PBS script Private (non-PBS) script
- Subsidy Patient pays the PBS contribution (or Safety Net amount when applicable) Usually full private price
Listing Medicine must be PBS-listed for the indication/quantity claimed Listing not required for claim (there is no PBS claim)
Authority rules Authority Required / STREAMLINED rules apply when listed that way Authority codes do not create PBS entitlement
Schedule law S4/S8 still apply S4/S8 still apply
Exam trap: An S4 medicine on a private script is still prescription-only. "Private" means funding pathway, not "OTC".
What Pharmacists Must Check on PBS Scripts
Before supply and claim, work through a disciplined checklist:
Patient eligibility — Medicare (or other eligible) details match the person presenting, and any concessional evidence is current if a concessional contribution is claimed.
Prescriber authority — Prescriber is authorised to prescribe that PBS item (including any specialist or authority constraints on the listing).
Item identity — Drug, form, strength, quantity, and repeats align with the PBS listing and any maximum quantities.
Indication / authority — If the item is Authority Required, approval or STREAMLINED code is present and appropriate.
Prescription formalities — Date, patient identifiers, prescriber details, signature (or compliant electronic prescription), and any required particulars for the schedule (especially S8).
Clinical and legal fitness to supply — No red flags that make supply unsafe or unlawful even if paperwork looks complete.
If a patient presents with a script that cannot be claimed as PBS (wrong quantity, missing authority, non-listed indication for that brand), options may include contacting the prescriber for correction, supplying privately if lawful, or declining supply when the prescription is inadequate.
Authority Required Versus Authority Required (STREAMLINED)
Many PBS items are restricted so that subsidy applies only when clinical criteria are met.
Authority Required (non-streamlined)
The prescriber must obtain prior authority approval (classically via Services Australia authority arrangements) before writing or finalising the prescription for PBS supply. The pharmacist should see evidence of authority on the prescription (for example an authority approval number) as required for that item. Without valid authority, do not process a PBS authority claim as if it were approved.
Authority Required (STREAMLINED)
For STREAMLINED items, the prescriber attests that the patient meets published streamlined criteria and writes a streamlined authority code on the prescription (or equivalent electronic field). The pharmacist does not ring for a new approval number in the same way as non-streamlined authority, but must still check :
- A streamlined code is present and appears consistent with the item/listing
- Quantity and repeats match what the listing allows under that authority pathway
Patient and clinical context are not obviously inconsistent with legitimate use (professional judgment remains)
Intern scenario — STREAMLINED authority: A patient presents an e-prescription for a STREAMLINED PBS medicine. The code field is blank. The correct action is not to invent a code or "guess" a common one. Contact the prescriber for a compliant script, or consider lawful private supply only if the medicine and prescription otherwise allow it and the patient accepts private pricing—and document the decision path.
Brand Substitution and A-Flagging (High Level)
PBS brand substitution (generic substitution) is tightly controlled:
Medicines may be treated as interchangeable for substitution purposes when they are a-flagged as equivalent under PBS arrangements.
If the prescriber has indicated brand substitution not permitted (or equivalent direction), supply the brand prescribed (or resolve with the prescriber).
Substitution decisions still require patient consent and professional judgment (allergy to excipients, previous intolerance, therapeutic index concerns).
Do not confuse a-flagging with "any brand of the same drug is always fine." Bioequivalence flagging, formulation differences, and device familiarity (for example inhalers) all matter in practice.
Safety Net (Brief)
The PBS Safety Net tracks eligible PBS (and certain RPBS) patient contributions over a calendar year . Once a family's recorded expenditure reaches the Safety Net threshold, further PBS medicines for that family are supplied at a reduced contribution for the rest of that year (concessional and general thresholds differ). Pharmacists support accurate recording (including Safety Net cards/records where used) so patients receive the entitlement they have earned. Exact dollar thresholds change over time—know the concept , not memorised figures, for the intern exam.
Special Access Scheme (SAS)
The Special Access Scheme provides pathways for access to unapproved therapeutic goods (medicines not on the Australian Register of Therapeutic Goods for the intended use, or not registered at all) when clinically justified. High-level categories:
Category Purpose (concept) Pharmacist focus
SAS Category A Seriously ill patients in certain life-threatening situations under defined criteria Confirm the Category A pathway is being used lawfully; retain/verify documentation expected for supply
SAS Category B Prescriber application pathway with TGA assessment for individual patient use Supply generally follows TGA authorisation for that patient; check authorisation matches medicine and patient
SAS Category C Notification pathway for specified unapproved goods meeting published criteria Notification/authorisation paperwork must match the product and circumstances
When SAS paperwork matters for supply: Treat SAS as a legal supply pathway , not a clinical preference label. Before releasing an unapproved medicine, confirm:
- The correct SAS category pathway is being used for that product and patient situation
- Prescriber obligations (application, notification, informed consent discussions) align with category rules
- The product identity, quantity, and patient match the authorisation/notification
- Storage, labelling, counselling, and records meet professional standards for an unapproved product
Intern scenario — SAS request: A patient asks the pharmacy to "order that overseas unapproved tablet" without any SAS documentation or clear prescriber pathway. Supply is not a simple wholesale order. Direct them to their specialist/prescriber to establish the lawful SAS (or other) pathway; do not improvise import or supply.
Intern scenario — non-PBS S4 supply: A patient has a valid private prescription for an S4 medicine that is not being claimed on PBS (patient choice, non-listed brand/quantity, or overseas visitor without PBS eligibility). You may supply as private if prescription and schedule requirements are met, price privately, and counsel as usual. Missing PBS authority is irrelevant to private supply—but missing S4 prescription formalities is not.
Professional Decision Pattern for Exam Items
When a stem involves PBS, authority, or SAS, ask in order:
Is supply schedule-lawful? (S2–S8 rules)
Is the prescription formally valid?
Is PBS claiming allowed? (listing, authority, eligibility, quantity)
If not PBS, is private supply appropriate and accepted?
If unapproved, is there a SAS/other lawful pathway with paperwork?
That sequence prevents the common error of focusing only on subsidy while missing legality—or the reverse.
- Exam Focus Summary
- Distinguish PBS entitlement from private supply and from schedule legality
- Treat STREAMLINED codes as required particulars, not optional annotations
- Use a-flagging + prescriber brand directions for substitution
- Explain Safety Net as a yearly contribution threshold mechanism
- Map SAS A/B/C to purpose and documentation discipline for unapproved medicines